Clinical trials: CYP19
Breast Cancer
500mg Fulvestrant Versus Exemestane in MBC
500mg Fulvestrant versus Exemestane in MBC
- Trial name
- NCT03575260
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
Hypogonadism, Diabetes
Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.
Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body.
- Conditions
- Hypogonadism, Diabetes, Sarcopenia, Osteoporosis
- Trial name
- NCT00104572
- Testing
- Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Calcium Cardone 500mg with vitamin D 400 IU
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Sexuality
Breast Cancer, Sexuality and Black Cohosh
The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.
- Trial name
- Cimicifuga (NCT02467686)
- Testing
- WHOQOL questionnaire, FSFI questionnaire, kupperman scale
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Irmandade da Santa Casa de Misericordia de Sao Paulo
Breast Cancer
Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy.
- Trial name
- ALPA (NCT03144037)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Metastatic Breast Cancer
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer (with and without prior therapies in metastatic setting, and during first-line aromatase…
- Trial name
- Pangeia-2 (NCT06417801)
- Where
- 6 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Breast Cancer Female, Joint Pain
Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer
Interventional, randomised, prospective, monocentric study
- Trial name
- ARHOMA2 (NCT04408560)
- Testing
- Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules), paracetamol (drug analgesic class1)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Institut Jean-Godinot
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Cancer, Osteoporosis, Osteopenia
Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention of bone loss occurring in post menopausal women with breast cancer treated with an aromatase inhibitor.
- Trial name
- NCT03518268
- Testing
- Vivomixx
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Breast Cancer
Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women
Breast cancer is the most frequently diagnosed cancer in women with the majority receiving an endocrine therapy (ET) in the adjuvant setting.
- Trial name
- NCT02480218
- Testing
- Neuropsychological test battery
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Menopause
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal women with early-stage breast cancer. This treatment induces bone loss and a higher risk of fractures.
- Conditions
- Breast Cancer, Menopause, Osteopenia
- Trial name
- RISAROS (NCT00859703)
- Testing
- Risedronate
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Adenomyosis of Uterus, Infertility Assisted Reproductive Technology
Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial
The AURA Trial seeks to improve fertility treatment for women affected by a condition known as adenomyosis. Adenomyosis often leads to heavy menstrual bleeding, pelvic pain, dyspareunia and can make it more difficult to achieve…
- Trial name
- AURA (NCT06985186)
- Testing
- Ultra-Long GnRH Agonists + Letrozole, Ultra-Long GnRH Agonists
- Where
- Spain
- Volunteers
- 162 people
- Sponsor
- University of Palermo
Hypogonadism, Hypogonadotropic, Obesity
Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism
The investigators have preliminary data suggesting that obese patients with hypogonadotropic hypogonadism (HHG) have minimal benefit from testosterone therapy likely because of its conversion to estradiol by the abundant…
- Trial name
- NCT03490513
- Testing
- anastrozole (1 mg/day)
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Baylor College of Medicine
Breast Cancer
Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors
Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer.
- Trial name
- AIMS (NCT01074320)
- Testing
- Other
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Breast Neoplasms
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
This is a prospective, single-arm, phase II study of 32 evaluable patients treated with NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy for hormone receptor positive (HR+), [i.e.
- Trial name
- NEOADAPT (NCT02689921)
- Testing
- Exemestane, Letrozole, Anastrozole
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Midwestern Regional Medical Center
Breast Cancer Survivors
Adherence to Aromatase Inhibitors: The Role of Partners
This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects.
- Trial name
- NCT02753985
- Testing
- Survey
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Breast Cancer, Breast Cancer Female
Effects of Aromatase Inhibitor Therapy on Muscle Function
This is a pilot study designed to examine changes in muscle function after Aromatase Inhibitor (AI) therapy, at both the molecular and clinical level.
- Trial name
- NCT03581552
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Tarah J Ballinger, MD
Breast Cancer
Adjuvant Post-Tamoxifen Exemestane Trial
The ATENA phase III randomized parallel-group multicenter trial is designed to compare 5 years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5-7 years…
- Trial name
- ATENA (NCT00810706)
- Testing
- exemestane
- Where
- Greece
- Volunteers
- 448 people
- Sponsor
- Hellenic Breast Surgeons Society